The effectiveness and safety of fixed low-dose prothrombin complex concentrates in patients requiring urgent reversal of warfarin (CME)

Transfusion

Volumn 53, Issue 7, 2013, Pages 1451-1458

  Varga, Cindy ^a   Al Touri, Sultan ^a   Papadoukakis, Stella ^a   Caplan, Stephen ^a   Kahn, Susan ^a   Blostein, Mark ^a  

^a MCGILL UNIVERSITY   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

FRESH FROZEN PLASMA; PROTHROMBIN COMPLEX; WARFARIN;

ADULT; AGED; ARTICLE; BLEEDING; BRAIN HEMORRHAGE; CEREBROVASCULAR ACCIDENT; DEEP VEIN THROMBOSIS; DRUG EFFICACY; DRUG SAFETY; FEMALE; HEART ATRIUM FIBRILLATION; HEART LEFT VENTRICLE ANEURYSM; HUMAN; INTERNATIONAL NORMALIZED RATIO; LIMB ISCHEMIA; LOW DRUG DOSE; LUNG EMBOLISM; MAJOR CLINICAL STUDY; MALE; MEDICAL RECORD REVIEW; NON ST SEGMENT ELEVATION MYOCARDIAL INFARCTION; OUTCOME ASSESSMENT; PLASMA TRANSFUSION; RETROSPECTIVE STUDY; SPLEEN INFARCTION; THROMBUS; TREATMENT RESPONSE;

ADULT; AGED; AGED, 80 AND OVER; ANTICOAGULANTS; BLOOD COAGULATION FACTORS; FEMALE; HUMANS; INTERNATIONAL NORMALIZED RATIO; MALE; MIDDLE AGED; RETROSPECTIVE STUDIES; WARFARIN;

EID: 84880228947     PISSN: 00411132     EISSN: 15372995     Source Type: Journal    
DOI: 10.1111/j.1537-2995.2012.03924.x     Document Type: Article

References (33)

1. Hart RG, Pearce LA, Aguilar MI,. Meta-analysis: antithrombotic therapy to prevent stroke in patients who have nonvalvular atrial fibrillation. Ann Intern Med 2007; 146: 857-867.
2. Furie B, Furie BC,. The molecular basis of blood coagulation. Cell 1988; 53: 505-518.
3. Ansell J, Hirsh J, Hylek E, Jacobson A, Crowther M, Palareti G,. Pharmacology and management of the vitamin K antagonists: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition). Chest 2008; 133: 160S-198.
4. Kimmel SE,. Warfarin therapy: in need of improvement after all these years. Expert Opin Pharmacother 2008; 9: 677-686.
5. Risk factors for stroke and efficacy of antithrombotic therapy in atrial fibrillation. Analysis of pooled data from five randomized controlled trials. Arch Intern Med 1994; 154: 1449-1457.
6. Beyth RJ, Quinn LM, Landefeld CS,. Prospective evaluation of an index for predicting the risk of major bleeding in outpatients treated with warfarin. Am J Med 1998; 105: 91-99.
7. Pisters R, Lane DA, Nieuwlaat R, de, Vos CB, Crijns HJ, Lip GY,. A novel user-friendly score (HAS-BLED) to assess one-year risk of major bleeding in atrial fibrillation patients: the Euro Heart Survey. Chest 2010; 138: 1093-1100.
8. Fihn SD, Callahan CM, Martin DC, McDonell MB, Henikoff JG, White RH,. The risk for and severity of bleeding complications in elderly patients treated with warfarin. The National Consortium of Anticoagulation Clinics. Ann Intern Med 1996; 124: 970-979.
9. Crowther MA, Ageno W, Garcia D, Wang L, Witt DM, Clark NP, Blostein MD, Kahn SR, Vesely SK, Schulman S, Kovacs MJ, Rodger MA, Wells P, Anderson D, Ginsberg J, Selby R, Siragusa S, Silingardi M, Dowd MB, Kearon C,. Oral vitamin K versus placebo to correct excessive anticoagulation in patients receiving warfarin: a randomized trial. Ann Intern Med 2009; 150: 293-300.
10. Ozgonenel B, O'Malley B, Krishen P, Eisenbrey AB,. Warfarin reversal emerging as the major indication for fresh frozen plasma use at a tertiary care hospital. Am J Hematol 2007; 82: 1091-1094.
11. Leissinger CA, Blatt PM, Hoots WK, Ewenstein B,. Role of prothrombin complex concentrates in reversing warfarin anticoagulation: a review of the literature. Am J Hematol 2008; 83: 137-143.
12. Baglin TP, Keeling DM, Watson HG,. Guidelines on oral anticoagulation (warfarin): third edition-2005 update. Br J Haematol 2006; 132: 277-285.
13. Silliman CC, McLaughlin NJ,. Transfusion-related acute lung injury. Blood Rev 2006; 20: 139-159.
14. Canadian Blood Services. National advisory committee on blood and blood products: recommendations for use of Octaplex in Canada. 2008.
15. Octapharma. Octaplex product monograph, 2007.
16. Riess HB, Meier-Hellmann A, Motsch J, Elias M, Kursten FW, Dempfle CE,. Prothrombin complex concentrate (Octaplex) in patients requiring immediate reversal of oral anticoagulation. Thromb Res 2007; 121: 9-16.
17. Hylek EM, Singer DE,. Risk factors for intracranial hemorrhage in outpatients taking warfarin. Ann Intern Med 1994; 120: 897-902.
18. Oden A, Fahlen M,. Oral anticoagulation and risk of death: a medical record linkage study. BMJ 2002; 325: 1073-1075.
19. Oden A, Fahlen M, Hart RG,. Optimal INR for prevention of stroke and death in atrial fibrillation: a critical appraisal. Thromb Res 2006; 117: 493-499.
20. Palareti G, Leali N, Coccheri S, Poggi M, Manotti C, D'Angelo A, Pengo V, Erba N, Moia M, Ciavarella N, Devoto G, Berrettini M, Musolesi S,. Bleeding complications of oral anticoagulant treatment: an inception-cohort, prospective collaborative study (ISCOAT). Italian Study on Complications of Oral Anticoagulant Therapy. Lancet 1996; 348: 423-428.
21. Makris M, Greaves M, Phillips WS, Kitchen S, Rosendaal FR, Preston EF,. Emergency oral anticoagulant reversal: the relative efficacy of infusions of fresh frozen plasma and clotting factor concentrate on correction of the coagulopathy. Thromb Haemost 1997; 77: 477-480.
22. Lubetsky A, Hoffman R, Zimlichman R, Eldor A, Zvi J, Kostenko V, Brenner B,. Efficacy and safety of a prothrombin complex concentrate (Octaplex) for rapid reversal of oral anticoagulation. Thromb Res 2004; 113: 371-378.
23. Boulis NM, Bobek MP, Schmaier A, Hoff JT,. Use of factor IX complex in warfarin-related intracranial hemorrhage. Neurosurgery 1999; 45: 1113-1118; discussion 1118-9.
24. Fredriksson K, Norrving B, Stromblad LG,. Emergency reversal of anticoagulation after intracerebral hemorrhage. Stroke 1992; 23: 972-977.
25. Lankiewicz MW, Hays J, Friedman KD, Tinkoff G, Blatt PM,. Urgent reversal of warfarin with prothrombin complex concentrate. J Thromb Haemost 2006; 4: 967-970.
26. Pabinger I, Brenner B, Kalina U, Knaub S, Nagy A, Ostermann H,. Prothrombin complex concentrate (Beriplex P/N) for emergency anticoagulation reversal: a prospective multinational clinical trial. J Thromb Haemost 2008; 6: 622-631.
27. Bobbitt L, Merriman E, Raynes J, Henderson R, Blacklock H, Chunilal S,. PROTHROMBINEX((R))-VF (PTX-VF) usage for reversal of coagulopathy: prospective evaluation of thrombogenic risk. Thromb Res 2011; 128: 577-582.
28. Yasaka M, Sakata T, Naritomi H, Minematsu K,. Optimal dose of prothrombin complex concentrate for acute reversal of oral anticoagulation. Thromb Res 2005; 115: 455-459.
29. Crowther MA, Douketis JD, Schnurr T, Steidl L, Mera V, Ultori C, Venco A, Ageno W,. Oral vitamin K lowers the international normalized ratio more rapidly than subcutaneous vitamin K in the treatment of warfarin-associated coagulopathy. A randomized, controlled trial. Ann Intern Med 2002; 137: 251-254.
30. Crowther MA, Julian J, McCarty D, Douketis J, Kovacs M, Biagoni L, Schnurr T, McGinnis J, Gent M, Hirsh J, Ginsberg J,. Treatment of warfarin-associated coagulopathy with oral vitamin K: a randomised controlled trial. Lancet 2000; 356: 1551-1553.
31. Yasaka M, Sakata T, Minematsu K, Naritomi H,. Correction of INR by prothrombin complex concentrate and vitamin K in patients with warfarin related hemorrhagic complication. Thromb Res 2002; 108: 25-30.
32. Goldstein JN, Rosand J, Schwamm LH,. Warfarin reversal in anticoagulant-associated intracerebral hemorrhage. Neurocrit Care 2008; 9: 277-283.
33. Fry JL, Arnold DM, Clase CM, Crowther MA, Holbrook AM, Traore AN, Warkentin TE, Heddle NM,. Transfusion premedication to prevent acute transfusion reactions: a retrospective observational study to assess current practices. Transfusion 2010; 50: 1722-1730.